Friday, August 29, 2008

PM (once again!) alerted us to a salient article -- more follow-up on the SEAS Vytorin-cancer data. While the full-version requires registration -- Therapeutics Daily offers a summary, for free, telling us all we really need to know:

The US FDA is aggressively tracking down all possible leads. Quoth the summary:

. . . .The Department of Defense is searching its medical database at FDA's request to investigate a potential link between cancer and the cholesterol-lowering drug Vytorin. The investigation is an example of FDA and DoD sharing more medical information and expertise in recent months, a DoD official says.

DoD is researching TRICARE for cancer diagnosis codes and the medications prescribed, says Rear Adm. Thomas McGinnis, a former FDA official who is responsible for TRICARE'S pharmacy operations. The investigation is intended to last nine months. . . .

[Emphasis supplied.]

This is the sort of diligence -- and active inter-agency cooperation -- our tax-dollars should garner, when public health and welfare might be at stake.

2 comments:

Anonymous
said...

This may be misleading.

The link was shown in individuals with aortic stenosis, whereas the DoD database likely has all comers. In addition the DoD's database's servicemen and women are likely skewed to a younger population that even if they are at risk of developing AS eventually much fewer are likely to have developed it already.

The only valid way to validate the results of the first study is to look at a similar population. Anything else will likely dilute out the relationship and is probably why when studies have been combined so far the association disappears.

As for mechanism it may have to do with the effect of statins on isoprenoid metabolism. Do a google search on isoprenoid or isoprenoid metabolism and it will become apparent why.

More FDA Resources. . .

Blog Archive

Senator Grassley's Concern

stats

FDA Drug Facts

The Condor. . . .

Legal Stuff; Creative Commons Statement 2008-2015

Nothing written, appearing, or linked to, on this site is intended to be individual legal, or investment, advice. Consult a financial or legal adviser before making any trade, or any other decision, based anything you read, or see, on this website. This website treats all U.S. viewers' visitor-paths -- and visits -- as public data. If you are from Europe, understand that this site can see -- but will not disclose to the public -- your visitor-path, in compliance with applicable E.U. directives. All material on this website is derived from public documents, and/or edited, modified, and derived from public domain sources, or in some cases, originally-created by the author(s) of this site. Any use of any proprietary image, document or other data is genuinely-intended by the author(s) to fall under the common-law "fair use" doctrine, as criticism of, and commentary on, matters of substantial public concern -- among them, the for-profit health care system in the Americas. If any person wishes to dispute this assertion of "fair use", please leave a comment in any of the comment-boxes, specifically-identifying the challenged material, and the basis for the challenge, on this site. The Site Administrator(s) will promptly consider the claim. In the same comment-box, the Site Administrator(s) will indicate the site's position on any such claim. This site is not-for-profit. Share, and share-a-like, licenses granted in, and to, all content. Copy-left 2008 though 2016.